We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+14.25%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$953M
AUM Growth
+$40.1M
Cap. Flow
-$46.4M
Cap. Flow %
-4.87%
Top 10 Hldgs %
94.29%
Holding
20
New
3
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$65.5M
2
SPNC
Spectranetics Corp
SPNC
+$15.5M
3
MRUS
Merus
MRUS
+$12.3M
4
FLXN
Flexion Therapeutics, Inc.
FLXN
+$11.9M
5
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$1.45M

Top Sells

Rank Stock Value
1
VTI icon
Vanguard Total Stock Market ETF
VTI
+$72.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$64.6M
3
PEN icon
Penumbra
PEN
+$12.1M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$2.37M
5
ELDN icon
Eledon Pharmaceuticals
ELDN
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 64.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$654B
$231M 24.24%
2,155,100
-682,000
-24% -$72.3M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$184M 19.34%
3,610,487
-1,300,000
-26% -$64.6M
INGN icon
3
Inogen
INGN
$167M
$178M 18.67%
3,549,320
– –
VGK icon
4
Vanguard FTSE Europe ETF
VGK
$30B
$98M 10.29%
2,101,000
– –
RETA
5
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$66.5M 6.98%
+3,367,763
New +$65.5M
CRVS icon
6
Corvus Pharmaceuticals
CRVS
$1.1B
$46M 4.83%
3,224,046
+70,000
+2% +$946K
TBRA
7
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$25.5M 2.67%
2,027,091
-254,314
-11% -$2.37M
CLCD
8
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$25M 2.62%
3,056,563
– –
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$23.3M 2.45%
685,863
+12,800
+2% +$416K
SPNC
10
DELISTED
Spectranetics Corp
SPNC
$20.9M 2.19%
1,117,002
+880,176
+372% +$15.5M
FLXN
11
DELISTED
Flexion Therapeutics, Inc.
FLXN
$14.2M 1.49%
+950,161
New +$11.9M
MRUS
12
DELISTED
Merus
MRUS
$11.3M 1.18%
+1,410,417
New +$12.3M
IVTY
13
DELISTED
Invuity, Inc
IVTY
$10.2M 1.08%
1,075,448
+139,255
+15% +$967K
NBRV
14
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.91M 0.83%
4,219
+719
+21% +$1.45M
WMGIZ
15
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
HTGM
16
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$3.48M 0.37%
7,112
– –
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.32B
$753K 0.08%
127,563
– –
ELDN icon
18
Eledon Pharmaceuticals
ELDN
$276M
$711K 0.07%
796
-2,111
-73% -$2.33M
GKOS icon
19
Glaukos
GKOS
$9.02B
– –
-101,106
Closed -$1.71M
PEN icon
20
Penumbra
PEN
$12.5B
– –
-263,191
Closed -$12.1M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q2 2016 Portfolio in Review

As of Q2 2016, Novo Holdings A/S held 20 positions worth $953M, up 4.4% from $912M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Novo Holdings A/S withdrew a net $46.4M in Q2 2016, closing 2 positions and reducing 4 holdings. Its most notable exit was Penumbra, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 56% a quarter earlier.

Against the trend, Novo Holdings A/S opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $66.5M.

  • Novo Holdings A/S's largest Q2 2016 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 3,367,763 shares worth $66.5M.
  • Novo Holdings A/S added most to Spectranetics Corp in Q2 2016, an estimated $15.5M increase.
  • Novo Holdings A/S's biggest Q2 2016 reduction was Vanguard Total Stock Market ETF, cutting an estimated $72.3M.
  • Novo Holdings A/S fully exited Penumbra in Q2 2016, selling an estimated $12.1M.
  • Novo Holdings A/S's ten largest holdings make up 94% of its $953M portfolio in Q2 2016.
  • Novo Holdings A/S opened 3 new positions and closed 2 in Q2 2016.
  • Novo Holdings A/S's portfolio value rose 4.4% quarter-over-quarter to $953M.

Based on Novo Holdings A/S's 13F filing for Q2 2016, filed 15 Aug 2016.